madman
Super Moderator
We are delighted to partner with Oxford Biodynamics for today’s episode with Dr. Robert Heaton, who joins us to discuss a ground-breaking new prostate cancer screening test that predicts the risk of prostate cancer with 94% accuracy, using a simple blood test.
Dr. Heaton is a board-certified pathologist. He completed his medical training at Georgetown University and then spent the next twenty years in the US Navy. After finishing his residency training in pathology, Dr. Heaton became the Director of Laboratory and Clinical Support Services for the National Naval Medical Center before joining various hospital pathology labs and life sciences companies. He is currently the Laboratory Medical Director for Oxford Biodynamics at their CLIA-certified clinical lab in Maryland, where he oversees the clinical operations of their liquid biopsy blood tests.
In today’s episode, we dive into the details of the innovative EpiSwitch Prostate Screening test, known as the PSE, designed to confirm the presence of prostate cancer, whether symptoms are present or not. This technological advancement is a game-changer! It empowers urologists by providing a precise tool to assess whether a patient should undergo a biopsy or opt for continued monitoring.
Stay tuned to learn how this simple yet powerful tool streamlines the screening process for men struggling with prostate cancer.
Show Highlights:
*At what age should men start getting checked for prostate cancer?
*What the screening for prostate cancer typically entails
*The importance of establishing a baseline to monitor how PSA changes over time
*Dr. Heaton dives into the details of the EpiSwitch PSA test
*How men can access the EpiSwitch PSA test
*Dr. Heaton discusses the accuracy of the EpiSwitch PSA test
*What is the expected turnaround time for the EpiSwitch PSC test results?
*Dr. Heaton explains the role of the Epi Switch PSA test in different scenarios
*The revolutionary EpiSwitch Prostate Screening test has remarkable accuracy in predicting prostate cancer risk through a simple blood test. It holds immense promise for men battling prostate cancer by providing urologists with a precise diagnostic tool and offering a streamlined approach for patients facing the complexities of prostate cancer.
